Dissecting pain pathways with conopeptides

用锥肽剖析疼痛通路

• 批准号: nhmrc : 351446
• 负责人: Prof David Adams
• 金额: $ 507.72万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Programs
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dissecting-pain-pathways-conopeptides/82852
• 关键词: Dissecting; pain; pathways; conopeptides

A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on pain research, the Program will significantly enhance the scope of existing multidisciplinary collaborations between the Cis Lewis Alewood, Adams and Christie, which have already made a considerable impact in the fields of pharmacology and neuroscience. The CIs also have considerable experience in the development of pain therapeutics, having discovered two conopeptides now under commercial development with AMRAD (AM336) and Xenome Ltd (Xen2174). This Program will discover and use highly selective conopeptides such as these to dissect the pharmacology of peripheral pain pathways and their projections into the central nervous system, and to identify and characterise new targets amenable to drug intervention. The long-term goal of the Program is to discover new targets in pain pathways and develop conopeptides that act on these targets in animal models of chronic pain. These molecules will be optimised within the Program to the point where they can be considered for pre-clinical development in collaboration with commercial partners.

开发更安全、更有效的疼痛治疗方法的一个主要障碍是慢性疼痛不同途径的定义不清。申请团队汇集了一套独特的研究专业知识，利用神经毒素在分子水平上定义神经系统的功能。申请人在理解和改善疼痛治疗方面也有共同的兴趣，特别是慢性疼痛，慢性疼痛仍然管理不善。通过对疼痛研究的关注，该计划将显著增强Cis Lewis Alewood， Adams和Christie之间现有的多学科合作范围，这些合作已经在药理学和神经科学领域产生了相当大的影响。CIs在开发疼痛治疗药物方面也有相当的经验，已经发现了两种康多肽，目前正在与AMRAD （AM336）和Xenome Ltd （Xen2174）进行商业开发。本项目将发现并使用这些高选择性的概念性肽来剖析外周疼痛通路及其投射到中枢神经系统的药理学，并确定和表征适合药物干预的新靶点。该项目的长期目标是发现疼痛通路中的新靶点，并在慢性疼痛动物模型中开发作用于这些靶点的概念性肽。这些分子将在项目中进行优化，以便与商业伙伴合作进行临床前开发。